Ding-Quan Qian

USPTO Granted Patents = 47 (Patent Applications = 25)

CIPO Patents = 11 (Patent Applications = 6)

EPO Patents = 23 (Patent Applications = 27)

Average Co-Inventor Count = 5.6

ph-index = 19

Forward Citations = 656(Granted Patents)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

47 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12247020 - Bipyrazole derivatives as JAK inhibitors (2025-03-11),

2. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2024-09-10),

3. 11981671 - Bicyclic pyrazolyl amines as CDK2 inhibitors (2024-05-14),

4. 11976073 - Bicyclic amines as CDK2 inhibitors (2024-05-07),

5. 11905275 - Bipyrazole derivatives as JAK inhibitors (2024-02-20),

6. 11851426 - Bicyclic amines as CDK2 inhibitors (2023-12-26),

7. 11673894 - Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors (2023-06-13),

8. 11673883 - Heterocyclic compounds as immunomodulators (2023-06-13),

9. 11667635 - Bicyclic heterocycles as FGFR4 inhibitors (2023-06-06),

10. 11591318 - Bipyrazole derivatives as JAK inhibitors (2023-02-28),

11. 11472791 - Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors (2022-10-18),

12. 11339149 - Heterocyclic compounds as immunomodulators (2022-05-24),

13. 11261191 - Imidazotriaines and imidazopyrimidines as kinase inhibitors (2022-03-01),

14. 11014923 - Bicyclic heterocycles as FGFR4 inhibitors (2021-05-25),

15. 11001571 - Bipyrazole derivatives as JAK inhibitors (2021-05-11),

Title: The Innovative Contributions of Ding-Quan Qian

Introduction

Ding-Quan Qian, based in Newark, Delaware, is a notable inventor recognized for his significant contributions in the field of pharmaceuticals. With an impressive portfolio of 46 patents, his work primarily focuses on developing innovative treatments targeting kinase pathways involved in various diseases, including cancer.

Latest Patents

Among his most recent inventions are two groundbreaking patents. The first, titled "Imidazotriazines and imidazopyrimidines as kinase inhibitors," presents novel compounds that serve as inhibitors of kinases such as c-Met. These compounds have potential applications in treating cancer and other diseases caused by the dysregulation of kinase pathways. The second patent, "Bicyclic pyrazolyl amines as CDK2 inhibitors," introduces bicyclic amines that act as inhibitors of cyclin-dependent kinase 2 (CDK2), along with pharmaceutical formulations and methods that could enhance cancer treatment.

Career Highlights

Ding-Quan Qian has played a crucial role in advancing drug development during his career. He is associated with Incyte Corporation and Incyte Holdings Corporation, where he has contributed to the research and development of therapeutic agents that address critical health challenges. His expertise in medicinal chemistry and pharmacology has paved the way for innovative solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Qian has collaborated with esteemed colleagues, including Wenqing Yao and Jincong Zhuo. These partnerships have been instrumental in fostering a collaborative research environment that encourages the sharing of ideas and the pursuit of cutting-edge discoveries in drug development.

Conclusion

Ding-Quan Qian's work exemplifies the spirit of innovation in biotechnology and pharmaceuticals. His patents not only enhance our understanding of kinase inhibition but also hold promise for the development of effective cancer therapies. As he continues his research, Qian remains a key figure in the ongoing quest for advancements in medical science and treatment options.

This text is generated by artificial intelligence and may not be accurate.